Differences in Proteasome Activity in Plasma of Patients with Hematologic Malignancy (original) (raw)

Blood, 2006

Abstract

The proteasome-dependent proteolytic pathway plays a crucial role in pathogenesis of hematologic malignancy, and as such it is a novel target for therapeutic drugs. High proteasome levels measured by conventional technique ELISA have been demonstrated in human malignant cells and in the plasma of patients with some hemopoietic malignancies and solid tumors. The objective of this study was to evaluate the activity of the 20S proteasome in the plasma from patients with hematologic malignancy. The study included normal subjects (n=15) and untreated patients with acute lymphoblastic leukemia (ALL, n=13), acute myeloblastic leukemia (AML, n=21), multiple myeloma (MM, n= 26) and chronic lymphocytic leukemia (CLL, n=30). The 20S proteasome activity in plasma (50μg of protein) was assayed spectrofluorimetrically using synthetic peptide substrate, Suc-Leu-Leu-Val-Tyr-AMC (100μmol/L) in the presence of 0.03% SDS that selectively activates the chymotrypsin-like activity of 20S proteasome. Enzy...

Halina Ostrowska hasn't uploaded this paper.

Let Halina know you want this paper to be uploaded.

Ask for this paper to be uploaded.